There is a huge unmet need in the rare disease community to invest in developing treatments. According to the US advocacy group Global Genes, there are more than 7,000 distinct rare diseases affecting 350,000,000 people worldwide and only 400 approved therapies. How can we adapt traditional recruitment strategies to target the right patients? The goal is to create tailored adaptive strategies aimed at extending reach and building relationships. There are many ways in which this can be done. In this first post of a series focused on adaptive recruitment for rare disease, I will explore the introduction of an early support program.